These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7710906)

  • 1. Mechanisms of acquired resistance to cisplatin.
    Andrews PA
    Cancer Treat Res; 1994; 73():217-48. PubMed ID: 7710906
    [No Abstract]   [Full Text] [Related]  

  • 2. Modulation of antitumor alkylating agents (AA).
    Teicher BA; Frei E
    Cancer Treat Res; 1991; 57():261-95. PubMed ID: 1686721
    [No Abstract]   [Full Text] [Related]  

  • 3. Mechanisms of resistance to cisplatin.
    Eastman A
    Cancer Treat Res; 1991; 57():233-49. PubMed ID: 1686719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines.
    Shellard SA; Fichtinger-Schepman AM; Lazo JS; Hill BT
    Anticancer Drugs; 1993 Aug; 4(4):491-500. PubMed ID: 8400352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of metallothionein, glutathione, glutathione S-transferases and DNA repair in resistance to platinum drugs in a series of L1210 cell lines made resistant to anticancer platinum agents.
    Hrubisko M; McGown AT; Fox BW
    Biochem Pharmacol; 1993 Jan; 45(1):253-6. PubMed ID: 8424817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporin A suppresses cisplatin-induced oncogene expression in human cancer cells.
    Scanlon KJ; Wang WZ; Han H
    Cancer Treat Rev; 1990 Dec; 17 Suppl A():27-35. PubMed ID: 2092869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into mechanisms of cisplatin resistance and potential for its clinical reversal.
    Gosland M; Lum B; Schimmelpfennig J; Baker J; Doukas M
    Pharmacotherapy; 1996; 16(1):16-39. PubMed ID: 8700790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Platinum salts: cytotoxic mechanisms of action, mechanisms of resistance of cancer cells, interactions with ionizing radiation, specificity of carboplatin].
    Rixe O
    Bull Cancer; 2000 Aug; 87 Spec No():7-15. PubMed ID: 11082717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical and clinical experience with cisplatin resistance.
    Marshall JL; Andrews PA
    Hematol Oncol Clin North Am; 1995 Apr; 9(2):415-29. PubMed ID: 7642471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro.
    Shellard SA; Hosking LK; Hill BT
    Cancer Res; 1991 Sep; 51(17):4557-64. PubMed ID: 1873800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin.
    Kasahara K; Fujiwara Y; Nishio K; Ohmori T; Sugimoto Y; Komiya K; Matsuda T; Saijo N
    Cancer Res; 1991 Jun; 51(12):3237-42. PubMed ID: 1645616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
    Lai SL; Hwang J; Perng RP; Whang-Peng J
    Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of cisplatin cytotoxicity in human ovarian carcinoma cell lines.
    Shellard S; Hosking L; Fichtinger-Schepman AM; Hill BT
    Biochem Soc Trans; 1990 Aug; 18(4):622. PubMed ID: 2276474
    [No Abstract]   [Full Text] [Related]  

  • 15. Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diammine-dichloroplatinum (II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation.
    Hill BT; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Bedford P
    Int J Radiat Oncol Biol Phys; 1990 Jul; 19(1):75-83. PubMed ID: 2380098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of resistance to alkylating agents.
    Colvin OM
    Cancer Treat Res; 1994; 73():249-62. PubMed ID: 7710907
    [No Abstract]   [Full Text] [Related]  

  • 17. Detection of DNA damage in transcriptionally active genes by RT-PCR and assessment of repair of cisplatin-induced damage in the glutathione S-transferase-pi gene in human glioblastoma cells.
    Brandt TY; Ali-Osman F
    Toxicol Appl Pharmacol; 1997 Mar; 143(1):22-9. PubMed ID: 9073588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cellular basis of the efficacy of the trinuclear platinum complex BBR 3464 against cisplatin-resistant cells.
    Perego P; Gatti L; Caserini C; Supino R; Colangelo D; Leone R; Spinelli S; Farrell N; Zunino F
    J Inorg Biochem; 1999 Oct; 77(1-2):59-64. PubMed ID: 10626355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro.
    Dempke WC; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Hill BT
    Carcinogenesis; 1992 Jul; 13(7):1209-15. PubMed ID: 1638688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
    Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
    Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.